Activity Details

Accredited By

Advancing Knowledge in Healthcare (AKH, Inc.)

Target Audience

This educational activity is designed for rheumatology healthcare professionals who manage patients with rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA 
• Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients 
• Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs 
• Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA 

Activity Description

Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they don’t cross the blood-brain barrier? We’ve sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We’ve also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinion against a patient’s true story. Will they match up?

Statement of Educational Need

Suboptimal management of patients with rheumatoid arthritis (RA) results in disability, inability to work, and substantial direct and indirect cost burden. Outcomes data from previous RA programs and from the literature indicate that despite the fact that effective use of disease-modifying antirheumatic drugs (DMARDs) greatly reduces the potential for joint destruction, systemic immune effects, and disability, rheumatology providers are not effectively utilizing DMARDs, switching drugs when appropriate, utilizing appropriate monitoring tools, using effective SDM strategies to optimize care, nor effectively selecting newer agents when making treatment decisions.

Faculty

Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Arthritis Research UK Professor, Rheumatology  
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases  
R. J. Fasenmyer Chair of Clinical Immunology  
Cleveland Clinic 
Cleveland, OH

Ernest Choy, MD, FRCP
Professor, Head of Rheumatology and Translational Research  
Division of Infection and Immunity  
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)  
Cardiff University School of Medicine  
Cardiff, UK

Conflict of Interest Policy/ Disclosure Statement

It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

• Leonard H. Calabrese, DO, has affiliations with AbbVie, Amgen, BMS, Crescendo, Genentech, Gilead, GSK, Horizon, Janssen, Lily, Pfizer, Sanofi-Genzyme, UCB (Consultant); AbbVie, BMS, Genentech, Horizon, Janssen, Lily, Sanofi (Speakers Bureau).
• Ernest Choy, MD, FRCP, has affiliations with Bio-Cancer, Biogen, Novartis, Novimmune, Pfizer, Roche, Sanofi, UCB (Contracted Research); AbbVie, Amgen, Biogen, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi (Consultant); Amgen, BMS, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Hospira, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, UCB (Speakers Bureau).
• Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair), has affiliations with AbbVie, Amgen, BMS, Gilead, Lilly, MSD, Novartis, Pfizer, Samsung, Sanofi (Consultant).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

• Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
• Sharon Powell has no affiliations with commercial interests to disclose.

 AKH Staff and Planners

• Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
• Patricia Brignoni, AKH, Director of Operations, has disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test and evaluation.

Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Accredited By

Advancing Knowledge in Healthcare (AKH, Inc.)

Target Audience

This educational activity is designed for rheumatology healthcare professionals who manage patients with rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA 
• Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients 
• Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs 
• Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA 

Activity Description

Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they don’t cross the blood-brain barrier? We’ve sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We’ve also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinion against a patient’s true story. Will they match up?

Statement of Educational Need

Suboptimal management of patients with rheumatoid arthritis (RA) results in disability, inability to work, and substantial direct and indirect cost burden. Outcomes data from previous RA programs and from the literature indicate that despite the fact that effective use of disease-modifying antirheumatic drugs (DMARDs) greatly reduces the potential for joint destruction, systemic immune effects, and disability, rheumatology providers are not effectively utilizing DMARDs, switching drugs when appropriate, utilizing appropriate monitoring tools, using effective SDM strategies to optimize care, nor effectively selecting newer agents when making treatment decisions.

Faculty

Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Arthritis Research UK Professor, Rheumatology  
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases  
R. J. Fasenmyer Chair of Clinical Immunology  
Cleveland Clinic 
Cleveland, OH

Ernest Choy, MD, FRCP
Professor, Head of Rheumatology and Translational Research  
Division of Infection and Immunity  
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)  
Cardiff University School of Medicine  
Cardiff, UK

Conflict of Interest Policy/ Disclosure Statement

It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

• Leonard H. Calabrese, DO, has affiliations with AbbVie, Amgen, BMS, Crescendo, Genentech, Gilead, GSK, Horizon, Janssen, Lily, Pfizer, Sanofi-Genzyme, UCB (Consultant); AbbVie, BMS, Genentech, Horizon, Janssen, Lily, Sanofi (Speakers Bureau).
• Ernest Choy, MD, FRCP, has affiliations with Bio-Cancer, Biogen, Novartis, Novimmune, Pfizer, Roche, Sanofi, UCB (Contracted Research); AbbVie, Amgen, Biogen, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi (Consultant); Amgen, BMS, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Hospira, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, UCB (Speakers Bureau).
• Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair), has affiliations with AbbVie, Amgen, BMS, Gilead, Lilly, MSD, Novartis, Pfizer, Samsung, Sanofi (Consultant).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

• Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
• Sharon Powell has no affiliations with commercial interests to disclose.

 AKH Staff and Planners

• Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
• Patricia Brignoni, AKH, Director of Operations, has disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test and evaluation.

Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Aimmune Therapeutics, Inc.

Activity Chair

Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL

• Disclosures:
  Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
  Contracted Research: Thermo Fisher Scientific, United Health Group

Faculty

Aikaterini Anagnostou, MD (Hons), MSc, PhD
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX

• Disclosures:
  Contracted Research (paid to institution): Aimmune

Christina E. Ciaccio, MD, MSc
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL

• Disclosures:
  Consulting Fee: Aimmune, Regeneron
  Speakers Bureau: Aimmune
  Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Overview

The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Target Audience

The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
• Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Aimmune Therapeutics, Inc.

Activity Chair

Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL

• Disclosures:
  Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
  Contracted Research: Thermo Fisher Scientific, United Health Group

Faculty

Aikaterini Anagnostou, MD (Hons), MSc, PhD
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX

• Disclosures:
  Contracted Research (paid to institution): Aimmune

Christina E. Ciaccio, MD, MSc
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL

• Disclosures:
  Consulting Fee: Aimmune, Regeneron
  Speakers Bureau: Aimmune
  Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Overview

The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Target Audience

The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
• Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

Target Audience

This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
• Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
• Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who require a change in therapy

Activity Description

How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at Digestive Disease Week® (DDW) 2019 exploring the latest in treat-to-target paradigms, the role of the JAK-STAT pathway, and related research on investigational JAK inhibitors in IBD treatment. Video excerpts from the symposium are available as modules making it easier for the learner to move easily from one excerpt to another. This activity qualifies for QPP Improvement Activity points.

Statement of Educational Need

Clinicians who treat patients with inflammatory disease such as IBD need to be updated on new and emerging therapies that will lead to individualized treatment and improved outcomes. Specifically, clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD.

Agenda

Video module highlights includes:

• What’s New in IBD Care? Choosing Targets and Selecting Therapy
• The JAK/STAT Signaling Pathway as a Target/Panel Discussion
• Available Data on the Safety of JAK Inhibition: Rheumatology Experience/Panel Discussion
• Available and Emerging JAK Inhibitors in IBD: Clinical Trials, Populations, and Safety/Panel Discussion

Faculty

Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY

Joel Pekow, MD
Assistant Professor of Medicine, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL

Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Bruce Sands, MD, MS, (Chair)
Consulting Agreements: AbbVie, Allergan, Amgen, Inc., Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Celgene, Celltrion Healthcare, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Gilead Sciences, Inc., Ironwood Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Pfizer, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Shire, Takeda, Theravance Biopharma R&D, Inc.
Grant/Research Support: Celgene
Honoraria Recipient: Takeda

Joel Pekow, MD, (Faculty)
Advisory Board: Janssen Pharmaceuticals, Inc. and Pfizer, Inc.
Consulting Agreement: Verastem
Grant Support: Takeda and AbbVie

Thomas Ullman, MD, (Faculty)
Advisory Board: Pfizer, Inc.
Honoraria Recipient: Janssen Pharmaceuticals, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MIPS Improvement Activity

Completion of this activity including the pre/posttest and follow-up assignments qualifies as a medium weight MIPS improvement activity under MACRA, and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive a certificate of completion after completing the follow-up survey.

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions about the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

Activity Details

Accredited By

Target Audience

This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
• Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
• Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who require a change in therapy

Activity Description

How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at Digestive Disease Week® (DDW) 2019 exploring the latest in treat-to-target paradigms, the role of the JAK-STAT pathway, and related research on investigational JAK inhibitors in IBD treatment. Video excerpts from the symposium are available as modules making it easier for the learner to move easily from one excerpt to another. This activity qualifies for QPP Improvement Activity points.

Statement of Educational Need

Clinicians who treat patients with inflammatory disease such as IBD need to be updated on new and emerging therapies that will lead to individualized treatment and improved outcomes. Specifically, clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD.

Agenda

Video module highlights includes:

• What’s New in IBD Care? Choosing Targets and Selecting Therapy
• The JAK/STAT Signaling Pathway as a Target/Panel Discussion
• Available Data on the Safety of JAK Inhibition: Rheumatology Experience/Panel Discussion
• Available and Emerging JAK Inhibitors in IBD: Clinical Trials, Populations, and Safety/Panel Discussion

Faculty

Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY

Joel Pekow, MD
Assistant Professor of Medicine, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL

Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Bruce Sands, MD, MS, (Chair)
Consulting Agreements: AbbVie, Allergan, Amgen, Inc., Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Celgene, Celltrion Healthcare, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Gilead Sciences, Inc., Ironwood Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Pfizer, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Shire, Takeda, Theravance Biopharma R&D, Inc.
Grant/Research Support: Celgene
Honoraria Recipient: Takeda

Joel Pekow, MD, (Faculty)
Advisory Board: Janssen Pharmaceuticals, Inc. and Pfizer, Inc.
Consulting Agreement: Verastem
Grant Support: Takeda and AbbVie

Thomas Ullman, MD, (Faculty)
Advisory Board: Pfizer, Inc.
Honoraria Recipient: Janssen Pharmaceuticals, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MIPS Improvement Activity

Completion of this activity including the pre/posttest and follow-up assignments qualifies as a medium weight MIPS improvement activity under MACRA, and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive a certificate of completion after completing the follow-up survey.

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions about the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

Activity Details

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Analyze regional and ethnic disparities in obesity
• Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
• Apply current practice guidelines to optimize screening, diagnosis, and treatment
• Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
• Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss

Activity Description

The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.

Statement of Educational Need

In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk Inc.

Activity Details

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Analyze regional and ethnic disparities in obesity
• Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
• Apply current practice guidelines to optimize screening, diagnosis, and treatment
• Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
• Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss

Activity Description

The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.

Statement of Educational Need

In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk Inc.